Bisphosphonate Prescribing

Normal bone undergoes continuous remodeling through coordinated osteoclast-mediated resorption and osteoblast-mediated formation. Osteoclasts are multinucleated cells derived from monocyte-macrophage lineage that resorb bone by secreting hydrochloric acid (dissolves hydroxyapatite mineral) and cathepsin K (degrades type I collagen matrix) into a sealed resorption lacuna (Howship lacuna). Osteoblasts then fill the resorption cavity with new osteoid (unmineralized collagen matrix) that subsequently mineralizes. The RANK/RANKL/OPG axis is the master regulatory pathway: osteoblasts express RANK ligand (RANKL), which binds to RANK receptors on osteoclast precursors, stimulating differentiation into mature osteoclasts. Osteoprotegerin (OPG), a decoy receptor produced by osteoblasts, competitively binds RANKL and inhibits osteoclastogenesis. In osteoporosis, an imbalance favoring resorption over formation leads to progressive bone loss — this occurs with estrogen deficiency (postmenopausal), glucocorticoid excess, aging, and hyperparathyroidism. Bisphosphonates are synthetic pyrophosphate analogs with a P-C-P backbone (replacing the P-O-P of pyrophosphate) that resist enzymatic hydrolysis. They bind with high affinity to hydroxyapatite on the bone surface, particularly at sites of active resorption. When osteoclasts ingest bisphosphonate-coated bone, nitrogen-containing bisphosphonates (alendronate, risedronate, ibandronate, zoledronic acid) inhibit farnesyl pyrophosphate synthase (FPPS) in the mevalonate...